6533b85dfe1ef96bd12be60d

RESEARCH PRODUCT

Pharmacologic Approaches to CDH: Evidence and Outcomes

Miguel J. A. LáinezAne Mínguez-olaondo

subject

Topiramatemedicine.medical_specialtyFluoxetineeducation.field_of_studyGabapentinbusiness.industryPopulationVenlafaxineChronic MigraineInternal medicinemedicineAmitriptylinebusinesseducationFlunarizinemedicine.drug

description

Chronic daily headache (CDH) is a highly prevalent condition that severely affects patient’s lives. Most patients with CDH experience chronic migraine (CM). The management of these patients is complex and includes acute and preventive pharmacological treatment. In CDH, the use of acute medication should be restricted to avoid the risk of medication-overuse headache. However, the use of preventive medication should be considered in all patients with CDH. There are few studies investigating the role of preventives in CDH, and the majority have CM. Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of CM. There are other neuromodulators, beta-blockers, calcium channel blockers, or antidepressants useful in the management of this population of patients. We will present evidence for the efficacy of each drug and for recommended use.

yearjournalcountryeditionlanguage
2018-09-04
https://doi.org/10.1007/978-3-319-91491-6_16